Dunlop A. Sinclair's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Sep 19, 2025
- Accession no.
- 0001193125-25-209537
- Filed
- Sep 19, 2025
- Trade date
- Sep 19, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $713.6K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dunlop A. SinclairCIK 0001721108 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2025 | Common Stock | SSaleDisposed | −31,092 | $22.95 | −$713,561.4 | 68,908 | Indirect | |
| Sep 19, 2025 | Common Stock | JOtherDisposed | −3,837 | $0.00 | $0 | 65,071 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.